196 related articles for article (PubMed ID: 18843500)
1. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration.
Schouten JS; La Heij EC; Webers CA; Lundqvist IJ; Hendrikse F
Graefes Arch Clin Exp Ophthalmol; 2009 Jan; 247(1):1-11. PubMed ID: 18843500
[TBL] [Abstract][Full Text] [Related]
2. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
Małgorzata F
Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
Retina; 2007; 27(4):439-44. PubMed ID: 17420695
[TBL] [Abstract][Full Text] [Related]
4. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
Algvere PV; Steén B; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
[TBL] [Abstract][Full Text] [Related]
5. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
Retina; 2006; 26(9):994-8. PubMed ID: 17151485
[TBL] [Abstract][Full Text] [Related]
6. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
Pedersen KB; Sjølie AK; Møller F
Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
[TBL] [Abstract][Full Text] [Related]
8. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
Kourlas H; Abrams P
Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
10. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
11. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.
Ladewig MS; Karl SE; Hamelmann V; Helb HM; Scholl HP; Holz FG; Eter N
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):17-25. PubMed ID: 17701197
[TBL] [Abstract][Full Text] [Related]
12. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.
Lazic R; Gabric N
Graefes Arch Clin Exp Ophthalmol; 2007 Jan; 245(1):68-73. PubMed ID: 17111146
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
14. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type.
Jonas JB; Libondi T; Ihloff AK; Harder B; Kreissig I; Schlichtenbrede F; Sauder G; Spandau UH
Acta Ophthalmol Scand; 2007 Aug; 85(5):563-5. PubMed ID: 17324219
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration.
Gamulescu MA; Radeck V; Lustinger B; Fink B; Helbig H
Int Ophthalmol; 2010 Jun; 30(3):261-6. PubMed ID: 19633973
[TBL] [Abstract][Full Text] [Related]
16. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.
Michels S; Rosenfeld PJ; Puliafito CA; Marcus EN; Venkatraman AS
Ophthalmology; 2005 Jun; 112(6):1035-47. PubMed ID: 15936441
[TBL] [Abstract][Full Text] [Related]
17. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
18. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration.
Garg S; Brod R; Kim D; Lane RG; Maguire J; Fischer D
Clin Exp Ophthalmol; 2008 Apr; 36(3):252-6. PubMed ID: 18412594
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment.
Fong KC; Kirkpatrick N; Mohamed Q; Johnston RL
Clin Exp Ophthalmol; 2008 Nov; 36(8):748-55. PubMed ID: 19128380
[TBL] [Abstract][Full Text] [Related]
20. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results.
Sacu S; Michels S; Prager F; Weigert G; Dunavoelgyi R; Geitzenauer W; Pruente C; Schmidt-Erfurth U
Eye (Lond); 2009 Dec; 23(12):2223-7. PubMed ID: 19169239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]